RNA5SP85: A Potential Drug Target and Biomarker (G100873318)
RNA5SP85: A Potential Drug Target and Biomarker
RNA5SP85 is a RNA molecule that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that contains 513 base pairs and is located in the X chromosome. RNA5SP85 has been shown to play a role in the development and progression of various diseases, including cancer.
The discovery of RNA5SP85
RNA5SP85 was first identified in the course of a study on the X chromosome using computational methods. The study showed that RNA5SP85 was highly expressed in various tissues and organs, including the brain, liver, and pancreas. The researchers also found that RNA5SP85 was co-expressed with other genes that are associated with various diseases, including cancer.
The potential drug target
RNA5SP85 has been shown to be involved in a variety of cellular processes that are associated with the development and progression of various diseases, including cancer. One of the most promising aspects of RNA5SP85 is its potential as a drug target. RNA5SP85 has been shown to interact with several protein molecules, including the protein encoded by the gene PIK3CA. This interaction suggests that RNA5SP85 may be a useful target for drugs that are designed to inhibit the activity of PIK3CA, which is a gene that is associated with the development of many diseases, including cancer.
The potential biomarker
In addition to its potential as a drug target, RNA5SP85 has also been shown to be a potential biomarker for several diseases, including cancer. One of the most promising aspects of RNA5SP85 is its ability to be downregulated in the presence of cancer cells. This suggests that RNA5SP85 may be a useful biomarker for diseases that are characterized by the over-expression of cancer cells.
Conclusion
RNA5SP85 is a RNA molecule that has been shown to play a role in the development and progression of various diseases, including cancer. Its potential as a drug target and biomarker makes it an attractive target for further research. Further studies are needed to fully understand the role of RNA5SP85 in diseases and to develop effective treatments based on its potential.
Protein Name: RNA, 5S Ribosomal Pseudogene 85
The "RNA5SP85 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP85 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RNA5SP91 | RNASE1 | RNASE10 | RNASE11 | RNASE11-AS1 | RNASE12 | RNASE13 | RNASE2 | RNASE2CP | RNASE3 | RNASE4 | RNASE6 | RNASE7 | RNASE8 | RNASE9 | RNASEH1 | RNASEH1-DT | RNASEH2A | RNASEH2B | RNASEH2B-AS1 | RNASEH2C | RNASEH2CP1 | RNASEK | RNASEL | RNASET2 | RND1 | RND2 | RND3 | RNF10 | RNF103 | RNF103-CHMP3 | RNF11 | RNF111 | RNF112 | RNF113A | RNF113B | RNF114 | RNF115 | RNF121 | RNF122 | RNF123 | RNF125 | RNF126 | RNF126P1 | RNF128 | RNF13 | RNF130 | RNF133 | RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222
